Potential of resveratrol in the treatment of interstitial lung disease

Abstract

Interstitial lung disease (ILD) is a heterogeneous group of diseases characterized by lung injury caused by lung fibroblast proliferation, interstitial inflammation, and fibrosis. Different cell signal transduction pathways are activated in response to various proinflammatory or fibrotic cytokines, such as IL-6, and these cytokines are increased in different ILDs. The overexpressed cytokines and growth factors in ILD can activate TGF-β/Smad2/3/4, NF-κB, and JAK/STAT signal transduction pathways, promote the activation of immune cells, increase the release of pro-inflammatory and pro-fibrotic factors, differentiate fibroblasts into myofibroblasts, and promote the occurrence and development of ILD. This finding suggests the importance of signal transduction pathways in patients with ILD. Recent evidence suggests that resveratrol (RSV) attenuates excessive inflammation and pulmonary fibrosis by inhibiting the TGF-β/Smad2/3/4, NF-κB, and JAK/STAT signal transduction pathways and overactivation of immune cells. In this review, advances in lung protection and the underlying mechanisms of RSV are summarized, and the potential efficacy of RSV as a promising treatment option for ILD is highlighted.

Researching New Drug Combinations with Senolytic Activity Using Senescent Human Lung Fibroblasts MRC-5 Cell Line

“…During senolysis by dasatinib and resveratrol, we did not observe any increase in IL-6 in the supernatant of cell culture, nor of IL-1α, as detected during senolysis induced by dasatinib and quercetin/ellagic acid. It is well documented that resveratrol causes anti-inflammatory activity by inhibiting NF-κB and counteracting cytokine production by immune cells [ 50 , 51 ]. A possibility is an anti-inflammatory or senomorphic activity inhibiting SASP release in parallel to senolytic action only observed with resveratrol in our culture system of MRC-5 senescent cells.…”

Perspectives on Post-COVID-19 Pulmonary Fibrosis Treatment

“…The current data suggest that resveratrol can impede the progression of certain autoimmune diseases and presents a positive therapeutic prospect in pulmonary fibrosis [104]. Experimental studies have demonstrated its effectiveness in alleviating interstitial lung diseases by inhibiting Smad and Smad7 expressions, lung fibroblast proliferation and differentiation, and reducing collagen deposits [102,105].…”

“…Recent evidence for resveratrol, a molecule present in various plants with antiinflammatory and antioxidant properties, reveals its ability to reduce the concentration of pro-inflammatory cytokines, thereby alleviating excessive inflammation and pulmonary fibrosis. These effects result from the inhibitions of TGF-β/Smad2/3/4, NF-κB, and Janus kinase/signal transducer and activator of transcription signal transduction pathways [102]. A clinical trial [103] is currently evaluating the therapeutic antifibrotic effects of resveratrol on patients discharged with COVID-19.…”